Valacyclovir: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
imported>Howard C. Berkowitz
No edit summary
Line 3: Line 3:
In [[pharmacology]] and [[virology]], '''valacyclovir''' ('''Valtrex''') is "a prodrug of [[acyclovir]]; 53% of oral dose excreted as acyclovir in the  urine; a 200-400% improvement on acyclovir; used in the management of [[Herpes simplex virus|HSV]] and [[Varicella zoster virus|VZV]] infections and the prophylaxis of [[Cytomegalovirus|HCMV]] infections; RN given  refers to the monohydrochloride L-valine isomer."<ref>{{MeSH}}</ref>
In [[pharmacology]] and [[virology]], '''valacyclovir''' ('''Valtrex''') is "a prodrug of [[acyclovir]]; 53% of oral dose excreted as acyclovir in the  urine; a 200-400% improvement on acyclovir; used in the management of [[Herpes simplex virus|HSV]] and [[Varicella zoster virus|VZV]] infections and the prophylaxis of [[Cytomegalovirus|HCMV]] infections; RN given  refers to the monohydrochloride L-valine isomer."<ref>{{MeSH}}</ref>


==History==
==History==  
Valtrex brand of valacyclovir was approved by the [[Food and Drug Administration]] in the [[United States]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 1995.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=020487 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2007.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076588 Drugs@FDA]. U S Food and Drug Administration</ref>
Valtrex brand of valacyclovir was approved by the [[Food and Drug Administration]] in the [[United States]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 1995.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=020487 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2007.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076588 Drugs@FDA]. U S Food and Drug Administration</ref>



Revision as of 08:21, 13 July 2010

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In pharmacology and virology, valacyclovir (Valtrex) is "a prodrug of acyclovir; 53% of oral dose excreted as acyclovir in the urine; a 200-400% improvement on acyclovir; used in the management of HSV and VZV infections and the prophylaxis of HCMV infections; RN given refers to the monohydrochloride L-valine isomer."[1]

History

Valtrex brand of valacyclovir was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 1995.[2] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2007.[3]

Pharmacology

Administration

Distribution

Metabolism

Excretion

Toxicity

Drug toxicity includes

Usage

Valacyclovir suppressive therapy can reduce the frequency of recurrence of herpes labialis from herpes simplex virus; however, this usage is not approved by the United States Food and Drug Administration.[4][5][6]

Valacyclovir suppressive therapy can reduce the frequency of recurrence of herpes genitalis from herpes simplex virus and this usage is approved by the United States Food and Drug Administration.[6]

External links

The most up-to-date information about Valacyclovir and other drugs can be found at the following sites.

References

  1. Anonymous (2024), Valacyclovir (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Drugs@FDA. U S Food and Drug Administration
  3. Drugs@FDA. U S Food and Drug Administration
  4. Gilbert SC (2007). "Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study.". J Drugs Dermatol 6 (4): 400-5. PMID 17668537.
  5. Baker D, Eisen D (2003). "Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.". Cutis 71 (3): 239-42. PMID 12661753.
  6. 6.0 6.1 Cernik C, Gallina K, Brodell RT (2008). "The treatment of herpes simplex infections: an evidence-based review.". Arch Intern Med 168 (11): 1137-44. DOI:10.1001/archinte.168.11.1137. PMID 18541820. Research Blogging. Cite error: Invalid <ref> tag; name "pmid18541820" defined multiple times with different content